Validation of Measurement Based Dose Volume Metrics for the Quality Assurance of VMAT Plans
Sankar Arumugam, Aitang Xing, Tony Young, David Thwaites and Lois Holloway
Article Type: Research Article | First Published: October 22, 2016
Ten each of prostate and head and neck (H&N) VMAT plans were considered for this study. Three types of errors were introduced into the original plans: gantry angle independent and dependent MLC errors, and gantry angle dependent dose error. The percentage difference in PTV-D95 between TPS and 3DVH was compared for no-error and error introduced plans....
A First Case of Male Breast Cancer Responding to Combined Aromatase Inhibitor/Palbociclib Therapy
Article Type: Case Report | First Published: October 19, 2016
For men with metastatic breast adenocarcinoma standard therapies typically involve the same therapies used for woman. Recently the FDA approved the aromatase inhibitor letrozole combined with the inhibitor of cyclin dependent kinase 4/6 (CDK4/6) palbociclib as first line therapy for women with metastatic breast cancer. Here we report a first case of a man with metastatic breast cancer whose tumor responded to palbociclib and letrozole. This combination might be effective for other men with metas...
Three-Dimensional Ultrasound: Is it Useful for Decision Making in the Management of Rectal Cancer? Is 3D Ultrasound Useful in Rectal Tumor?
Sthela M Murad-Regadas, Romulo M Almeida, Rosilma G Lima Barreto, Doryane MR Lima, Francisco Sergio Pinheiro Regadas, Lusmar Veras Rodrigues, Francisco Coracy C Monteiro, Paulo G Oliveira, Joao Batista Barreto and Univaldo Etsuo Sagae
Article Type: Original Article | First Published: October 17, 2016
Consecutive patients treated for rectal cancer or adenomas in 4 colorectal centers in Brazil were included. Patients with early-stage rectal cancer identified by 3D-US were assigned to receive resection only, and those with a later stage were assigned to receive CRT. A second 3D-US was performed after CRT to detect the presence of residual tumor and metastatic lymph nodes or complete response....